Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 5/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658402 | 0.83 | — | — | |
| SCHEMBL658949 | 0.71 | IDO1 (0.32) | — | |
| SCHEMBL3646724 | 0.66 | LMNA (0.39) | PGK1GSK3BMAP4K2 | |
| SCHEMBL14941607 | 0.63 | AOC1 (0.34) | PGK1KDM4E | |
| SCHEMBL28715816 | 0.63 | MAPT (0.38) | PGK1KDM4ECD38 | |
| SCHEMBL12497291 | 0.62 | CRHR1 (0.48) | PGK1GSK3BMAP4K2KDM4E | |
| SCHEMBL12037997 | 0.60 | PGK1 (0.42) | PGK1GSK3BMAP4K2 | |
| SCHEMBL24463612 | 0.59 | MAPK8 (0.37) | PGK1KDM4ECD38 | |
| SCHEMBL21360995 | 0.59 | MAPK1 (0.38) | PGK1MAP4K4GSK3BMAP4K2 | |
| SCHEMBL22499429 | 0.59 | UTS2R (0.40) | PGK1MAP4K4GSK3BMAP4K2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | PGK1 427/4885MAP4K4 41/4885GSK3B 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.